The successes of this long-standing dialogue are considered to be the drug program's access to all registered MS treatment therapies in Europe, including treatment of spasticity. This situation has evolved over the years. Today, not only do doctors have a full range of therapeutic options, but most importantly, patients can co-determine the therapy that best suits their treatment needs. Importantly, one that also suits their lifestyle and work. This provides an invaluable sense of security, because we know that if one therapy is not right for us, there are options to change to another. MS is a chronic disease, the patient stays with it for the rest of his or her life, and thinking about what will happen in two, five or ten years is an important prospect, but it is also sometimes a concern for people with chronic diseases. It is also an undisputed success that access to treatment with most therapies is in line with drug registration indications.
Therapies are evaluating and evolving. Drugs that were only possible to administer in a hospital setting have, over time, taken on a friendlier form of administration to...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
